

Continuing Education/Continuing Medical Education (CE/CME)

**Next Generation Sequencing Panels for Hereditary Cancer**

WHEN: May 5, 2025 — 6:30 AM

**Presentation purpose:**

* This web-based training (WBT) module will review next generation sequencing (NGS) panels for inherited cancer risk and broadly how this information is used to help guide medical management decision-making for patients. This may include increased surveillance for cancer, chemoprevention, preventative surgical options and cancer treatment decision-making. The information in the WBT will include types of panel genetic tests, how they are performed, what the different results of genetic testing mean with respect to patient care, and what to look for when choosing a genetic testing laboratory to use. We will also review when NGS panels for hereditary cancer are appropriate to offer to patients, taking into account challenges and psychosocial factors that come into play, informed consent for this testing and when to refer to a board-certified genetic counselor. Currently, genetic testing to determine the risk for developing cancer (hereditary cancer testing) is being ordered inconsistently by health care professionals.

**Learning objectives:**

* 1 Describe different types of panel tests for hereditary cancer genetic testing.
* 1 Explain what a variant of uncertain significance (VUS) result means for a patient in terms of their medical care.
* 2 Describe situations in which a patient should be referred to a board-certified genetic counselor for evaluation and consideration of hereditary cancer test.
* 2 Discuss the different types of results that may arise from a panel genetic test and how they may or may not impact patient care.
* 3 Outline some of the challenges that may arise from ordering a panel genetic test.
* 3 Discuss treatment options for individuals who have a germline mutation.
* 4 Understand when it is appropriate to refer a patient for genetic counseling.

**Target audience:**

This activity is designed for the interdisciplinary audience including the following:

Specialties: Oncology

**Accreditation**

In support of improving patient care, Ascension is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Credit designation:**



This activity was planned by and for the healthcare team, and learners will receive 1.00 IPCE credit(s) for learning and change.



Ascension designates this Enduring Material for a maximum of 1.00 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



This activity is awarded 1.00 ANCC contact hour(s). (based on 60 minutes per contact hour)



Ascension has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.









**Faculty/Course Director/Planners:**

Ascension has selected all faculty participating in this activity. It is the policy of Ascension that all CE/CME planning committees, faculty, authors, editors, and staff disclose relationships with commercial interests upon nomination or invitation of participation. Disclosure documents are reviewed for potential conflicts of interest and if relevant, they are resolved prior to confirmation of participation. Only those participants who have no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this activity.

**Conflict of Interest:**

In accordance with the ACCME Standards for Commercial Support, it is the policy of Ascension to ensure balance, independence, objectivity and scientific rigor in all CE/CME activities.

Full disclosure of conflicts and conflict resolution will be made in writing via handout materials or syllabus.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Stephanie Cohen, MS, LCGC | Other Planning Committee Member | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Journal of Genetic counseling (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-UT Southwestern genetic counseling study (Relationship has ended)|Independent Contractor (included contracted research)-Cancer Support Community - 03/14/2025 |
| DAWN M NIXON, MS, CGC | Course Director | Nothing to disclose - 03/24/2025 |
| Ginger Kreyling, BSN, RN, CN-BN, CGRA | Nurse Planner | Nothing to disclose - 10/29/2024 |
| Emily Lichtenberg, MS, LCGC | Other Planning Committee Member | Nothing to disclose - 04/04/2025 |
| Anne (Katie) Cavanaugh, PA-C, Physician Assistant | PA Planner | Nothing to disclose - 04/08/2025 |
| Erica Giblin, MD | Physician Planner | Nothing to disclose - 04/04/2025 |

**Commercial Support:**

No commercial interest was received for this CE/CME activity.